MBP and myeloid sarcoma: MBP-specific Th17 and Th1 cells are higher in both primary progressive MS (PPMS) and SPMS (68, 73–75), suggesting therapeutic approaches restoring Teff:Treg balance may not only benefit RRMS, but also progressive MS.